US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mira Pharma

1.22

-0.0300-2.40%

Post-market: 1.17-0.0500-4.10%19:58 EDT

Volume:208.78K

Turnover:248.12K

Market Cap:20.51M

PE:-2.40

High:1.25

Open:1.25

Low:1.17

Close:1.25

Loading ...

Overview Company News Filings

EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain

MIRA Announces Approval of Important Testing

Zacks Small Cap Research

Rising High: Exclusive talk with pharmaceutical development company MIRA

What Is Pump.fun? Everything About the Token Creation Platform

Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation

Simply Wall St.

Whale loses $500K on MIRA token as charity token trend gains ground

Crypto Whale Turns $81.3K into $13.36M Profit with MIRA and FARTCOIN Tokens: A 1030x Return

MIRA Pharmaceuticals submits IND to FDA for Ketamir-2

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

Mira Pharmaceuticals Inc - Submits Ind Application to FDA for Ketamir-2

THOMSON REUTERS

EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment

MIRA Makes Major Strides

Zacks Small Cap Research

Mira Pharmaceuticals Inc: Submission of Investigational New Drug (Ind) Application by End of 2024

THOMSON REUTERS

Mira Pharmaceuticals Inc: Validates Ketamir-2'S Safety Profile With No Adverse Findings, Paving Way for Ind Submission by Year-End

THOMSON REUTERS

Mira Pharmaceuticals Inc: Plans to Initiate Phase I Clinical Trials for Ketamir-2 in Q1 of 2025

THOMSON REUTERS

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain

MIRA Pharmaceuticals Appoints New Board Member and Chairman

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

MIRA Continues Solid Financial Management

Zacks Small Cap Research

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MIRA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MIRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":1.22,"timestamp":1746820800000,"preClose":1.25,"halted":0,"volume":208780,"hourTrading":{"tag":"盘后","latestPrice":1.17,"preClose":1.22,"latestTime":"19:58 EDT","volume":3526,"amount":4237.1238,"timestamp":1746835137580},"delay":0,"floatShares":13154337,"shares":16813654,"eps":-0.508455,"marketStatus":"Market Closed","change":-0.03,"latestTime":"05-09 16:00:00 EDT","open":1.25,"high":1.25,"low":1.17,"amount":248121.417544,"amplitude":0.064,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.508455,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":1.25,"preHourTrading":{"tag":"盘前","latestPrice":1.24,"preClose":1.25,"latestTime":"09:27 EDT","volume":9858,"amount":11402.898442,"timestamp":1746797272390},"postHourTrading":{"tag":"盘后","latestPrice":1.17,"preClose":1.22,"latestTime":"19:58 EDT","volume":3526,"amount":4237.1238,"timestamp":1746835137580},"volumeRatio":0.1155793994934075},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","floatShares":13154337,"roa":"-127.59%","roe":"-238.90%","lyrEps":-0.508455,"volumeRatio":0.1155793994934075,"shares":16813654,"dividePrice":0,"high":1.25,"amplitude":0.064,"preClose":1.25,"low":1.17,"week52Low":0.51,"pbRate":"9.32","week52High":5.01,"institutionHeld":0,"latestPrice":1.22,"eps":-0.508455,"divideRate":0,"volume":208780,"delay":0,"ttmEps":-0.508455,"open":1.25,"prevYearClose":1.14,"prevWeekClose":1.16,"prevMonthClose":1.16,"prevQuarterClose":0.98,"fiveDayClose":1.16,"twentyDayClose":0.8436,"sixtyDayClose":1.13},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MIRA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516789675","title":"EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2516789675","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516789675?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:45","pubTimestamp":1741092318,"startTime":"0","endTime":"0","summary":"On Tuesday, the Israeli Ministry of Health and the Institutional Review Board  approved MIRA Pharmaceuticals, Inc.'s  Phase 1 trial for Ketamir-2, the company's novel oral ketamine analog in development for neuropathic pain.In December, MIRA Pharmaceuticals submitted an Investigational New Drug  application to the FDA to start human trials for Ketamir-2.MIRA's preclinical studies demonstrate Ketamir-2's superior efficacy, safety, and optimized pharmacokinetics, supporting its advancement into Phase 1 clinical trials.Also Read: EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain. Subject recruitment is scheduled to begin in the first quarter of 2025.The study will be conducted at the Clinical Pharmacology Unit, Hadassah Medical Center in Jerusalem, Israel.The Phase 1, randomized, double-blind, placebo-controlled, single-center study evaluates the safety, tolerability, and pharmacokinetics of orally administered Ketamir-2 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-mira-pharmaceuticals-kick-starts-124518585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2517606488","title":"MIRA Announces Approval of Important Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2517606488","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517606488?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:08","pubTimestamp":1741086480,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals  is a clinical-stage pharmaceutical company that focuses on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company also acquired the rights to Ketamir, which, in layman’s terms, is a potential derivative of the antidepressant ketamine that has shown indications of having fewer side effects, working more rapidly, and having the opportunity to impact millions of patients that have not responded to other, existing treatments. We have written about the exciting preclinical results for Ketamir-2, the company’s novel oral ketamine analog, and the company just announced the beginning of clinical trials, illustrating further important advancement in the approval process.We remain extremely positive on MIRA, and this announcement is yet further confirmation that company management is on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-announces-approval-important-testing-110800394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2504914905","title":"Rising High: Exclusive talk with pharmaceutical development company MIRA","url":"https://stock-news.laohu8.com/highlight/detail?id=2504914905","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504914905?lang=en_us&edition=fundamental","pubTime":"2025-01-17 00:15","pubTimestamp":1737044118,"startTime":"0","endTime":"0","summary":"In this edition of “Rising High,” The Fly conducted an exclusive interview with Erez Aminov, Chairman & Chief Executive Officer of MIRA Pharmaceuti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rising-high-exclusive-talk-with-pharmaceutical-development-company-mira?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rising-high-exclusive-talk-with-pharmaceutical-development-company-mira?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2503321810","title":"What Is Pump.fun? Everything About the Token Creation Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2503321810","media":"BE[IN]CRYPTO","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503321810?lang=en_us&edition=fundamental","pubTime":"2025-01-13 15:21","pubTimestamp":1736752912,"startTime":"0","endTime":"0","summary":"While market-making, order-flow, and trading platforms like DEXs find their product market fit with institutional crypto investors, Pump.fun appeals to the average retail trader via meme coins. The platform has shifted the dynamics of speculative trading in crypto markets and, as a result, lowered the barrier to entry for many users. Here’s what you need to know about the meme coin launchpad in 2025.Pump.fun makes it easy for anyone to launch a meme coin on Solana, lowering technical and financial barriers.Its step-function bonding curve mechanism drives trading by adjusting token prices at discrete supply intervals.Despite anti-rug-pull measures, scams and volatility remain a concern.Pump.fun’s unfiltered, decentralized model can establish creative freedom but also invites controversial behavior.Pros and cons of Pump.funThe enigma of Pump.fun’s open-access modelFrequently asked questions. my ultimate goal is for pump dot fun to be the most fun place on the internetif I don't achieve t","market":"us","thumbnail":"https://beincrypto.com/wp-content/uploads/2024/09/bic_Generic_Memecoins_2-covers_neutral-850x478.jpg.optimal.jpg","type":0,"news_type":0,"thumbnails":["https://beincrypto.com/wp-content/uploads/2024/09/bic_Generic_Memecoins_2-covers_neutral-850x478.jpg.optimal.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://beincrypto.com/learn/what-is-pump-fun/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"beincrypto_highlight","symbols":["TON.USD.CC","DEC","DBC","APT.USD.HKCC","BK4213","TON.USD.HKCC","RNDR.USD.HKCC","BK4585","BK4007","BK4588","APT.USD.CC","MIRA"],"gpt_icon":0},{"id":"2501144214","title":"Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2501144214","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501144214?lang=en_us&edition=fundamental","pubTime":"2025-01-05 21:16","pubTimestamp":1736083001,"startTime":"0","endTime":"0","summary":"So, the natural question for MIRA Pharmaceuticals  shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.Since its cash burn is increasing , MIRA Pharmaceuticals shareholders should still be mindful of the possibility it will require more cash in the future. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-were-not-too-131641039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","QID","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4007","QLD","NQmain","SQQQ","MNQmain","PSQ","BK4585",".IXIC","BK4588","LU2210150020.SGD","TQQQ","IE00BKPKM429.USD","BK4112","USAW.SI","USJW.SI","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","NVIW.SI","TSYW.SI","NDAQ"],"gpt_icon":1},{"id":"2494046388","title":"Whale loses $500K on MIRA token as charity token trend gains ground","url":"https://stock-news.laohu8.com/highlight/detail?id=2494046388","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494046388?lang=en_us&edition=fundamental","pubTime":"2024-12-27 21:54","pubTimestamp":1735307687,"startTime":"0","endTime":"0","summary":"A whale lost $500K on the MIRA token, which built up hype around being linked to rare disease research. The token was tied to Siqi Chen, co-founder of Serious Business and Runway, with no previous connections to crypto or memes.The MIRA token saw active trading after a big part of the supply was sent to Siqi Chen, co-founder of Serious Business and Runway. The initial hype around the token suggested the asset would be used to fund research into rare diseases. However, soon after the launch, MIRA went through extreme volatility.Recently, MIRA wiped as much as $500K from a whale trader, who poured more than $1.56M into the token. The buyer is still holding, though. Within hours, the value of the token holdings fell to $718,000, extending its downward trend. Despite the noble cause, once Chen sold his share and whales took profit, the token did not find support from anywhere else.Before whales realized profits, Chen held up to $18M worth of MIRA tokens. Initially, the share was worth $400","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/676eb1a88a03c8196e11c888/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2494877454","title":"Crypto Whale Turns $81.3K into $13.36M Profit with MIRA and FARTCOIN Tokens: A 1030x Return","url":"https://stock-news.laohu8.com/highlight/detail?id=2494877454","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494877454?lang=en_us&edition=fundamental","pubTime":"2024-12-27 17:31","pubTimestamp":1735291872,"startTime":"0","endTime":"0","summary":"A crypto whale has received widespread attention after earning a huge profit by accumulating massive amounts of Chains of War (MIRA) and Fartcoin (FARTCOIN) tokens. The whale swapped $69,100 for MIRA ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/676e73df3b1253069be45e7a/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["RNDR.USD.HKCC","TON.USD.CC","MIRA","BK4007","TON.USD.HKCC","APT.USD.HKCC","APT.USD.CC"],"gpt_icon":0},{"id":"2492717661","title":"MIRA Pharmaceuticals submits IND to FDA for Ketamir-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2492717661","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492717661?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:15","pubTimestamp":1734617715,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals (MIRA), has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for Ketamir-2, its nove...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-submits-ind-to-fda-for-ketamir-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-submits-ind-to-fda-for-ketamir-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2492517061","title":"MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2492517061","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492517061?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:00","pubTimestamp":1734616800,"startTime":"0","endTime":"0","summary":"MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. , a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced that it has submitted an Investigational New Drug  application to the U.S. Food and Drug Administration  for Ketamir-2, its novel oral ketamine analog for the treatment of neuropathic pain. The IND submission marks a major step in advancing Mira's lead drug candidate while reflecting its commitment to meeting milestones and timelines.Ketamir-2 is specifically designed to address the limitations of existing treatments through its selective targeting of the NMDA receptor. By binding to a specific site on the NMDA receptor with low affinity, Ketamir-2 significantly reduces the risk of psychotropic effects commonly associated with traditional ketamine. Furthermore, it is not a substrate for P-glycoprotein , which allows for better oral absorption and enhanced blood-brain barrier ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-submits-ind-ketamir-140000120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","BK4007","BK4159","ABVC","BK4139","CAGR"],"gpt_icon":0},{"id":"2492134178","title":"Mira Pharmaceuticals Inc - Submits Ind Application to FDA for Ketamir-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2492134178","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492134178?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:34","pubTimestamp":1734615257,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nFWN3NK0FY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2492075921","title":"EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2492075921","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492075921?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:25","pubTimestamp":1734614707,"startTime":"0","endTime":"0","summary":"On Thursday, MIRA Pharmaceuticals, Inc.  said it submitted an Investigational New Drug  application to the FDA to start human trials for Ketamir-2, its novel oral ketamine analog for neuropathic pain.An IND is submitted to propose studying an unapproved drug or an approved product for a new indication or in a new patient population.The company’s IND application includes comprehensive data and reports detailing Ketamir-2’s pharmacology, pharmacokinetics, and toxicology, along with results from both in vitro and in vivo studies, including validated neuropathic pain disease models.In parallel with the submission, the company is conducting a neurotoxicity study, as required by the FDA’s written feedback, to support the initiation of human dosing in the U.S.Also Read: MIRA Pharmaceuticals’ Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain. MIRA is also advancing MIRA-55, with preclinical trials targeting memory, cognition, and anxiety, and plans to ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XlKpU41fb7dZ50sdK1frtQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/660745cf8b3ba74acd71ae58169044f2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XlKpU41fb7dZ50sdK1frtQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/660745cf8b3ba74acd71ae58169044f2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-mira-pharmaceuticals-files-fda-132507382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2492170619","title":"MIRA Makes Major Strides","url":"https://stock-news.laohu8.com/highlight/detail?id=2492170619","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492170619?lang=en_us&edition=fundamental","pubTime":"2024-12-19 18:05","pubTimestamp":1734602700,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals  is a preclinical-stage pharmaceutical company that is about to be a clinical-stage company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company also acquired the rights to Ketamir, which, in layman’s terms, is a potential derivative of the antidepressant ketamine that has shown indications of having fewer side effects, working more rapidly, and having the opportunity to impact millions of patients that have not responded to other, existing treatments. We have written about the exciting preclinical results for Ketamir-2, the company’s novel oral ketamine analog, and the company just released further study results that, in our view, boost the potential for the treatment.We remain extremely positive on MIRA, and this announcement is yet further confirmation that the p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-makes-major-strides-100500635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2490158340","title":"Mira Pharmaceuticals Inc: Submission of Investigational New Drug (Ind) Application by End of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2490158340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490158340?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:47","pubTimestamp":1733838431,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nFWN3NB02J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2490015866","title":"Mira Pharmaceuticals Inc: Validates Ketamir-2'S Safety Profile With No Adverse Findings, Paving Way for Ind Submission by Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2490015866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490015866?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:47","pubTimestamp":1733838431,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nFWN3NB02J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2490015860","title":"Mira Pharmaceuticals Inc: Plans to Initiate Phase I Clinical Trials for Ketamir-2 in Q1 of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2490015860","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490015860?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:47","pubTimestamp":1733838431,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nFWN3NB02J:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2490531016","title":"MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2490531016","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490531016?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:30","pubTimestamp":1733837400,"startTime":"0","endTime":"0","summary":"Strong Safety Profile Validated Across Studies, Setting the Stage for Clinical Trials in Neuropathic Pain. MIAMI, FL / ACCESSWIRE / December 10, 2024 / MIRA Pharmaceuticals, Inc. , a preclinical-stage pharmaceutical company, proudly announces the successful completion of its current Good Laboratory Practice  preclinical safety program for Ketamir-2, a novel oral ketamine analog. The results confirm no adverse findings, clearing a critical milestone as the Company progresses toward submitting its Investigational New Drug  application by year-end 2024.\"Our commitment to advancing Ketamir-2 into clinical trials as quickly as possible reflects our strategic focus on generating proof-of-concept data that positions MIRA for a potential M&A transaction or strategic partnership,\" said Erez Aminov, CEO and Chairman of MIRA. \"This milestone demonstrates our ability to execute efficiently and reinforces our dedication to delivering innovative, safe, and effective treatments for patients suffering","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-validates-ketamir-2s-133000864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4144","MIRA","GLP","BK4590"],"gpt_icon":0},{"id":"2490013384","title":"EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2490013384","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490013384?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:15","pubTimestamp":1733836517,"startTime":"0","endTime":"0","summary":"On Tuesday, MIRA Pharmaceuticals, Inc.  said it completed the current Good Laboratory Practice preclinical safety program for Ketamir-2, a novel oral ketamine analog.The results confirm no adverse findings, clearing a critical milestone as the company progresses toward submitting its Investigational New Drug  application by year-end 2024.Also Read: MIRA Pharmaceuticals’ Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain. The company says that by demonstrating Ketamir-2’s robust safety profile in comprehensive preclinical studies, MIRAhas significantly de-risked this critical aspect of drug development.This milestone positions the company for a smoother regulatory pathway, potentially increasing the likelihood of successful clinical outcomes.Cardiovascular Safety in Dogs: No adverse effects were noted at therapeutic doses.Building on the Phase 1 findings, MIRA plans to initiate a Phase 2a proof-of-concept study in Q4 2025, focusing on patients wi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PTh5gnwlEiCInrLg5qLVtA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/fd337e3099329830e61f441b2093ca6d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PTh5gnwlEiCInrLg5qLVtA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/fd337e3099329830e61f441b2093ca6d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-mira-pharmaceuticals-validates-ketamir-131517884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2485426470","title":"MIRA Pharmaceuticals Appoints New Board Member and Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2485426470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485426470?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:48","pubTimestamp":1732225696,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has shared an update. MIRA Pharmaceuticals, Inc. announces a significant leadership change as Michael Jerman...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-appoints-new-board-member-and-chairman?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-appoints-new-board-member-and-chairman?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2484011565","title":"MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2484011565","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484011565?lang=en_us&edition=fundamental","pubTime":"2024-11-20 20:44","pubTimestamp":1732106640,"startTime":"0","endTime":"0","summary":"Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical-Stage Company and Advancing Breakthroughs in Pain and Depression Treatment. MIAMI, FL / ACCESSWIRE / November 20, 2024 / MIRA Pharmaceuticals, Inc. , a preclinical-stage pharmaceutical company, is pleased to announce the selection of The Centre for Human Drug Research  in Leiden, The Netherlands, as the site for its Phase I/IIa clinical trial of Ketamir-2, a novel oral ketamine analog. Recruitment for the trial is set to begin in Q1 2025, with initial safety and efficacy results from the Phase I study in healthy subjects expected in the second half of 2025. The Phase IIa study, planned to start in Q4 2025, will focus on diabetic neuropathy patients, with initial human efficacy results anticipated in the first half of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-reveals-innovative-phase-iia-124400230.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2483832346","title":"MIRA Continues Solid Financial Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2483832346","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483832346?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:00","pubTimestamp":1731495600,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals  is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company also acquired the rights to Ketamir, which, in layman’s terms, is a potential derivative of the antidepressant ketamine that has shown indications of having fewer side effects, working more rapidly, and having the opportunity to impact millions of patients that have not responded to other, existing treatments. We have written about the exciting preclinical results for Ketamir-2, the company’s novel oral ketamine analog, and the company just released further study results that, in our view, boost the potential for the treatment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-continues-solid-financial-management-110000694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","MIRA"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":60,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MIRA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MIRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MIRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1741233600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MIRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MIRA","date":"2025-05-09","current":-2.676427,"percent":0.227818,"low":-15.501022,"twenty":-3.087659,"median":-1.92061,"eighty":-1.335972,"high":-0.648567,"avg":-3.302253,"sd":3.549745,"marketCap":21017067},"quantilePoints":[{"date":"2023-08-04","current":-15.501022,"twenty":-15.501022,"median":-15.501022,"eighty":-15.501022,"marketCap":109409161},{"date":"2023-08-11","current":-14.407729,"twenty":-14.826558,"median":-14.407729,"eighty":-13.088417,"marketCap":101692488},{"date":"2023-08-18","current":-13.611953,"twenty":-14.407729,"median":-13.779485,"eighty":-13.130299,"marketCap":96075752},{"date":"2023-08-25","current":-13.193124,"twenty":-14.407729,"median":-13.42348,"eighty":-13.109358,"marketCap":93119575},{"date":"2023-09-01","current":-13.137838,"twenty":-14.303022,"median":-13.371126,"eighty":-13.130299,"marketCap":92729360},{"date":"2023-09-07","current":-12.209294,"twenty":-13.9889,"median":-13.365891,"eighty":-13.071664,"marketCap":86175515},{"date":"2023-09-15","current":-7.434221,"twenty":-13.678966,"median":-13.193124,"eighty":-12.686741,"marketCap":52472141},{"date":"2023-09-22","current":-11.507289,"twenty":-13.511434,"median":-13.119829,"eighty":-11.928492,"marketCap":66366173},{"date":"2023-09-29","current":-12.263336,"twenty":-13.419292,"median":-13.046534,"eighty":-11.42538,"marketCap":70726534},{"date":"2023-10-06","current":-12.045492,"twenty":-13.402539,"median":-12.816178,"eighty":-11.507289,"marketCap":69470159},{"date":"2023-10-13","current":-7.586097,"twenty":-13.383691,"median":-12.460173,"eighty":-11.225373,"marketCap":43751419},{"date":"2023-10-20","current":-8.457473,"twenty":-13.371126,"median":-12.263336,"eighty":-10.752267,"marketCap":48776920},{"date":"2023-10-27","current":-6.022746,"twenty":-13.371126,"median":-12.209294,"eighty":-9.627991,"marketCap":34735079},{"date":"2023-11-03","current":-3.818677,"twenty":-13.36275,"median":-12.045492,"eighty":-8.098671,"marketCap":22023518},{"date":"2023-11-10","current":-3.793048,"twenty":-13.343902,"median":-11.968606,"eighty":-7.418465,"marketCap":21875709},{"date":"2023-11-17","current":-6.622011,"twenty":-13.222442,"median":-11.712319,"eighty":-5.991992,"marketCap":49959391},{"date":"2023-11-24","current":-6.405718,"twenty":-13.159952,"median":-11.404903,"eighty":-6.252529,"marketCap":48327581},{"date":"2023-12-01","current":-6.955071,"twenty":-13.133315,"median":-11.148487,"eighty":-6.405718,"marketCap":52472141},{"date":"2023-12-08","current":-3.546106,"twenty":-13.117734,"median":-10.762135,"eighty":-5.961237,"marketCap":26753401},{"date":"2023-12-15","current":-2.977946,"twenty":-13.096793,"median":-9.110163,"eighty":-5.156496,"marketCap":22466945},{"date":"2023-12-22","current":-2.066929,"twenty":-13.063287,"median":-8.611245,"eighty":-3.869935,"marketCap":15593833},{"date":"2023-12-29","current":-2.155092,"twenty":-13.025592,"median":-8.1243,"eighty":-3.839181,"marketCap":16258973},{"date":"2024-01-05","current":-2.272643,"twenty":-12.962768,"median":-7.893642,"eighty":-3.762396,"marketCap":17145826},{"date":"2024-01-12","current":-1.929591,"twenty":-12.874813,"median":-7.640782,"eighty":-3.079823,"marketCap":14557693},{"date":"2024-01-19","current":-1.608482,"twenty":-12.807801,"median":-7.444864,"eighty":-2.883906,"marketCap":12135106},{"date":"2024-01-26","current":-2.292235,"twenty":-12.642964,"median":-7.355439,"eighty":-2.366683,"marketCap":17293635},{"date":"2024-02-02","current":-1.880808,"twenty":-12.498268,"median":-7.111805,"eighty":-2.256969,"marketCap":14189649},{"date":"2024-02-09","current":-1.950359,"twenty":-12.397348,"median":-6.788541,"eighty":-2.206031,"marketCap":14714371},{"date":"2024-02-16","current":-2.01795,"twenty":-12.300188,"median":-6.405718,"eighty":-2.186439,"marketCap":15224311},{"date":"2024-02-23","current":-2.076725,"twenty":-12.241719,"median":-6.022746,"eighty":-2.135501,"marketCap":15667738},{"date":"2024-03-01","current":-1.968971,"twenty":-12.205282,"median":-5.750179,"eighty":-2.104154,"marketCap":14854789},{"date":"2024-03-08","current":-1.86102,"twenty":-12.137755,"median":-4.971969,"eighty":-2.061052,"marketCap":14040362},{"date":"2024-03-15","current":-2.409785,"twenty":-12.045492,"median":-3.957585,"eighty":-2.070847,"marketCap":18180488},{"date":"2024-03-22","current":-2.46856,"twenty":-12.014738,"median":-3.869935,"eighty":-2.084562,"marketCap":18623915},{"date":"2024-03-28","current":-2.135501,"twenty":-11.968606,"median":-3.818677,"eighty":-2.096317,"marketCap":16111164},{"date":"2024-04-05","current":-1.258227,"twenty":-11.958355,"median":-3.592948,"eighty":-2.059093,"marketCap":15076502},{"date":"2024-04-12","current":-1.209008,"twenty":-11.917349,"median":-3.095496,"eighty":-2.037542,"marketCap":14486745},{"date":"2024-04-19","current":-1.033719,"twenty":-11.835337,"median":-3.026925,"eighty":-1.978767,"marketCap":12386381},{"date":"2024-04-26","current":-1.1102,"twenty":-11.507289,"median":-2.977946,"eighty":-1.941738,"marketCap":13302796},{"date":"2024-05-03","current":-0.996589,"twenty":-11.466334,"median":-2.723253,"eighty":-1.872971,"marketCap":11941476},{"date":"2024-05-10","current":-0.925167,"twenty":-11.297339,"median":-2.546927,"eighty":-1.840684,"marketCap":11085663},{"date":"2024-05-17","current":-0.812651,"twenty":-11.251002,"median":-2.419581,"eighty":-1.782849,"marketCap":10043611},{"date":"2024-05-24","current":-1.05244,"twenty":-11.138236,"median":-2.390193,"eighty":-1.612165,"marketCap":13007178},{"date":"2024-05-31","current":-0.956764,"twenty":-11.09723,"median":-2.331418,"eighty":-1.319904,"marketCap":11824708},{"date":"2024-06-07","current":-0.922081,"twenty":-10.81147,"median":-2.30203,"eighty":-1.233679,"marketCap":11396062},{"date":"2024-06-14","current":-0.849247,"twenty":-10.732533,"median":-2.292235,"eighty":-1.18937,"marketCap":10495906},{"date":"2024-06-21","current":-0.875439,"twenty":-10.189973,"median":-2.272643,"eighty":-1.090284,"marketCap":10819607},{"date":"2024-06-28","current":-0.77737,"twenty":-9.841423,"median":-2.272643,"eighty":-1.073193,"marketCap":9607575},{"date":"2024-07-05","current":-0.687674,"twenty":-9.256415,"median":-2.262847,"eighty":-1.05424,"marketCap":8499008},{"date":"2024-07-12","current":-0.717692,"twenty":-8.841445,"median":-2.213868,"eighty":-1.045463,"marketCap":8870009},{"date":"2024-07-15","current":-0.704656,"twenty":-8.774265,"median":-2.213868,"eighty":-1.033719,"marketCap":8708897},{"date":"2024-08-02","current":-2.906169,"twenty":-8.772416,"median":-2.213868,"eighty":-1.036655,"marketCap":35917550},{"date":"2024-08-09","current":-2.535423,"twenty":-8.703509,"median":-2.262847,"eighty":-1.048424,"marketCap":31335476},{"date":"2024-08-16","current":-2.173611,"twenty":-8.390838,"median":-2.272643,"eighty":-1.04904,"marketCap":27788063},{"date":"2024-08-23","current":-2.162049,"twenty":-8.098671,"median":-2.248016,"eighty":-1.051378,"marketCap":27640254},{"date":"2024-08-30","current":-2.162049,"twenty":-7.95515,"median":-2.242981,"eighty":-1.05289,"marketCap":27640254},{"date":"2024-09-06","current":-1.826758,"twenty":-7.791127,"median":-2.23142,"eighty":-1.05469,"marketCap":23353798},{"date":"2024-09-13","current":-1.549276,"twenty":-7.650578,"median":-2.222644,"eighty":-1.05842,"marketCap":19806385},{"date":"2024-09-20","current":-1.341164,"twenty":-7.640782,"median":-2.194276,"eighty":-1.060611,"marketCap":17145826},{"date":"2024-09-27","current":-1.237108,"twenty":-7.586097,"median":-2.16783,"eighty":-1.073193,"marketCap":15815546},{"date":"2024-10-04","current":-1.352726,"twenty":-7.444864,"median":-2.155092,"eighty":-1.083185,"marketCap":17293635},{"date":"2024-10-11","current":-1.24867,"twenty":-7.434221,"median":-2.147009,"eighty":-1.095016,"marketCap":15963355},{"date":"2024-10-18","current":-1.260232,"twenty":-7.355439,"median":-2.135501,"eighty":-1.1102,"marketCap":16111164},{"date":"2024-10-25","current":-1.437761,"twenty":-7.355439,"median":-2.125705,"eighty":-1.110817,"marketCap":18380747},{"date":"2024-10-31","current":-2.79918,"twenty":-7.270245,"median":-2.125705,"eighty":-1.18937,"marketCap":35785525},{"date":"2024-11-08","current":-2.150279,"twenty":-7.139233,"median":-2.135501,"eighty":-1.21299,"marketCap":27489790},{"date":"2024-11-15","current":-2.170683,"twenty":-7.064784,"median":-2.135501,"eighty":-1.218696,"marketCap":24399222},{"date":"2024-11-22","current":-1.856409,"twenty":-6.974663,"median":-2.135501,"eighty":-1.224412,"marketCap":20866673},{"date":"2024-11-29","current":-1.90061,"twenty":-6.755235,"median":-2.115909,"eighty":-1.229612,"marketCap":21363499},{"date":"2024-12-06","current":-1.753275,"twenty":-6.551481,"median":-2.101597,"eighty":-1.233136,"marketCap":19707413},{"date":"2024-12-13","current":-1.650142,"twenty":-6.445215,"median":-2.081117,"eighty":-1.235736,"marketCap":18548154},{"date":"2024-12-20","current":-1.473341,"twenty":-6.405718,"median":-2.071827,"eighty":-1.237108,"marketCap":16560852},{"date":"2024-12-27","current":-1.768009,"twenty":-6.252529,"median":-2.060335,"eighty":-1.241733,"marketCap":19873022},{"date":"2025-01-03","current":-1.694342,"twenty":-5.991992,"median":-2.057134,"eighty":-1.250581,"marketCap":19044979},{"date":"2025-01-10","current":-1.959543,"twenty":-5.868974,"median":-2.057134,"eighty":-1.258227,"marketCap":22025933},{"date":"2025-01-17","current":-1.768009,"twenty":-5.779566,"median":-2.037542,"eighty":-1.258227,"marketCap":19873022},{"date":"2025-01-24","current":-1.664875,"twenty":-5.732546,"median":-2.035768,"eighty":-1.259831,"marketCap":18713762},{"date":"2025-01-31","current":-1.856409,"twenty":-5.367769,"median":-2.010846,"eighty":-1.260232,"marketCap":20866673},{"date":"2025-02-07","current":-1.723809,"twenty":-5.033478,"median":-1.997597,"eighty":-1.260232,"marketCap":19376196},{"date":"2025-02-14","current":-1.753275,"twenty":-4.268723,"median":-1.967235,"eighty":-1.268496,"marketCap":19707413},{"date":"2025-02-21","current":-1.635408,"twenty":-4.064306,"median":-1.959359,"eighty":-1.271301,"marketCap":18382545},{"date":"2025-02-28","current":-1.502808,"twenty":-3.940055,"median":-1.950359,"eighty":-1.271793,"marketCap":16892069},{"date":"2025-03-07","current":-1.488074,"twenty":-3.869935,"median":-1.934829,"eighty":-1.271793,"marketCap":16726460},{"date":"2025-03-14","current":-1.841676,"twenty":-3.869935,"median":-1.920187,"eighty":-1.27873,"marketCap":20701065},{"date":"2025-03-21","current":-1.797476,"twenty":-3.846869,"median":-1.893243,"eighty":-1.290292,"marketCap":20204239},{"date":"2025-03-28","current":-1.620675,"twenty":-3.823803,"median":-1.885876,"eighty":-1.294917,"marketCap":18216937},{"date":"2025-04-04","current":-1.927027,"twenty":-3.8033,"median":-1.893243,"eighty":-1.309909,"marketCap":15132288},{"date":"2025-04-11","current":-1.806267,"twenty":-3.701093,"median":-1.885876,"eighty":-1.319904,"marketCap":14183998},{"date":"2025-04-17","current":-2.291021,"twenty":-3.602316,"median":-1.885876,"eighty":-1.323783,"marketCap":17990609},{"date":"2025-04-25","current":-2.128723,"twenty":-3.467739,"median":-1.885876,"eighty":-1.330657,"marketCap":16716134},{"date":"2025-05-02","current":-2.440901,"twenty":-3.248312,"median":-1.90061,"eighty":-1.333733,"marketCap":19167565},{"date":"2025-05-09","current":-2.676427,"twenty":-3.087659,"median":-1.92061,"eighty":-1.335972,"marketCap":21017067}],"updateTime":1746994544300}}}